Home›Sugammadex

Sugammadex

Also known as: Bridion

Route: Intravenous

3 interactions on record

Sugammadex has 3 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Oral Contraceptives, Toremifene. Patients taking Sugammadex should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Moderate: 2

Moderate (2)

Sugammadex + Oral Contraceptives— Sugammadex may bind to progestogen, decreasing exposure and efficacy. Patients must use additional non-hormonal contrace…
Sugammadex + Toremifene— Concomitant use can delay recovery to TOF ratio of 0.9 due to displacement of vecuronium or rocuronium from the sugammad…

Sugammadex + Oral Contraceptives🟡Moderate

Sugammadex may bind to progestogen, decreasing exposure and efficacy. Patients must use additional non-hormonal contraception for 7 days after administration.

Sugammadex + Toremifene🟡Moderate

Concomitant use can delay recovery to TOF ratio of 0.9 due to displacement of vecuronium or rocuronium from the sugammadex complex.

Sugammadex + Progesteroneℹ️Unknown

7.4 Interference with Laboratory Tests BRIDION may interfere with the serum progesterone assay.

Contraindications

4 CONTRAINDICATIONS BRIDION is contraindicated in patients with known hypersensitivity to sugammadex or any of its components. Hypersensitivity reactions that occurred varied from isolated skin reactions to serious systemic reactions (i.e., anaphylaxis, anaphylactic shock) and have occurred in patients with no prior exposure to sugammadex [see Warnings and Precautions (5.1) , Adverse Reactions (6) ] . Known hypersensitivity to sugammadex or any of its components. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are no clinical trial data on BRIDION use in pregnant women to inform any drug-associated risks. The available data from the pharmacovigilance safety database and published literature on BRIDION use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, there was no evidence of malformations following daily intravenous administration of sugammadex to rats and rabbits during organogenesis at exposures of up to 6 and 8 times, respectively, the maximum recommended human dose (MRHD) of 16 mg/kg. However, there was an increase in the incidence of incomplete ossification of the sternebra and reduced fetal body weights in the rabbit study at 8 times the MRHD, which is a dose level in which maternal toxicity was also observed. In a pre- and postnatal development study, sugammadex treatment resulted in an increase in early postnatal loss, which correlated with maternal behavior (increased incidence of pup cannibalism), at exposures equivalent to the MRHD and higher (see Data ) . The background risk of major birth defects and miscarriage for the indicated population are unknown. However, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. Data Animal Data In an embryofetal development study in rats, pregnant animals received daily intravenous administration of sugammadex at 0, 20, 100, and 500 mg/kg (0.2, 1, and 6 times the MRHD of 16 mg/kg/day, respectively, based on AUC comparison) during organogenesis (Gestational Days 6-17). No treatment-related maternal and embryofetal changes were observed. In another embryofetal development study, pregnant New Zealand white rabbits received daily intravenous administration of sugammadex at 0, 20, 65, 200 mg/kg (0.6, 2, and 8 times the MRHD, respectively, based on AUC comparison) during o

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.